It is estimated that in humans almost all fermented SCFA are absorbed by the colonocytes and only 5% are excreted with stool, equivalent to 530 millimoles per day
A significant risk of cardiovascular disease, cardiovascular death, and cardiometabolic risk factors is also associated with obesity
Beginning in July 2026, CMS will launch a temporary Medicare GLP-1 Bridge program offering eligible Part D beneficiaries access to certain GLP-1 weight loss medications for obesity at an estimated $50 monthly copay
Cognitive function in obese individuals improves substantially with weight loss alone, but the direct central GLP-1R effects may contribute additional benefit beyond what weight reduction alone would predict
Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial
To learn more about our high manufacturing standards, please visit our Know Us page